Résumé
Constitutive activating mutations in KIT and platelet-derived growth factor receptor α (PDGFRα) are heavily involved in the pathobiology of gastrointestinal stromal tumors (GISTs). This disease has served as an effective "proof-of-concept" model for targeting gain-of-function kinase mutations in cancer. This review discusses the current standard of care in terms of pharmacotherapy in the management of localized and metastatic GISTs.
langue originale | Anglais |
---|---|
Numéro d'article | 1689 |
journal | F1000Research |
Volume | 6 |
Les DOIs | |
état | Publié - 1 janv. 2017 |